Atazanavir

Active ingredient description

Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
J05AE08
Atazanavir
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Medicines

Atazanavir is the active ingredient of these drugs:

Drug
Countries
ANOVAVIR

South Africa

ATAHIV

South Africa

ATAZOR

South Africa

REYATAZ

Australia Austria Brazil Canada Cyprus

Atazanavir is also found within below combination drugs:

EVOTAZ

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
REYATAZ Hard capsules
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

QZU4H47A3S - ATAZANAVIR

CAS registry number

198904-31-3 - atazanavir

SNOMED-CT

413592000 - Atazanavir (substance)

Next: Usage